Innovation: Longitudinal Assay Screening

Apr 26, 2019

Credit SDPB

David Ure, Chief Executive Officer and Founder of Inanovate. He is also the co-inventor of the Longitudinal Assay Screening technology. Inanovate, Inc. is a life science company specializing in the development of blood tests for cancer and autoimmune diseases. The company recently secured $3.1 million investment to support breast cancer detection technology.

Support for technology and innovation reporting comes from SDN Communications, your business broadband provider. Learn more at sdncommunications.com